This document describes a proposed randomized controlled trial comparing the clinical success rate of Lefamulin to Moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) among Bangladeshi adults. The primary objective is to demonstrate the superiority of Lefamulin over Moxifloxacin in clinical success rate. Secondary objectives include evaluating early clinical response, clinical response at test-of-cure, microbiological response, safety, and mortality. The trial would enroll Bangladeshi adults aged 18+ who have symptoms and signs of CABP, including radiographic evidence of pneumonia. Participants must meet inclusion criteria related to symptoms and vital signs and be appropriate for oral antibiotic therapy. Those receiving other antibiotics or with